http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Oct 2026 16:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MESABI+TRUST++++++++++++++For%3A+Oct+15/27193867.html si-local-file:///var/storage/secattach/20261015/27193867.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MESABI+TRUST++++++++++++++For%3A+Oct+15/27193867.html Thu, 15 Oct 2026 16:35:00 -0400 MSB http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Announcement+of+No+Distribution/27193346.html <p> NEW YORK--(BUSINESS WIRE)-- The Trustees of Mesabi Trust (NYSE: MSB) have determined that no distribution has been declared this quarter, and no distribution will be paid in November 2026, with respect to Units of Beneficial Interest. This compares to a thirty-four cents ($0.34) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of declaring no distribution this quarter reflects consideration of several factors. The Trustees’ current distribution determination primarily reflects that the total royalty payments received by the Trust of $1,807,779 on July 30, 2026, from Cleveland-Cliffs Inc. (“Cliffs”), the parent company of http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Announcement+of+No+Distribution/27193346.html Thu, 15 Oct 2026 16:05:00 -0400 MSB http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Announcement+of+No+Distribution/27193346.html <p> NEW YORK--(BUSINESS WIRE)-- The Trustees of Mesabi Trust (NYSE: MSB) have determined that no distribution has been declared this quarter, and no distribution will be paid in November 2026, with respect to Units of Beneficial Interest. This compares to a thirty-four cents ($0.34) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of declaring no distribution this quarter reflects consideration of several factors. The Trustees’ current distribution determination primarily reflects that the total royalty payments received by the Trust of $1,807,779 on July 30, 2026, from Cleveland-Cliffs Inc. (“Cliffs”), the parent company of http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Announcement+of+No+Distribution/27193346.html Thu, 15 Oct 2026 16:05:00 -0400 MSB http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MESABI+TRUST++++++++++++++For%3A+Jul+31/27053248.html si-local-file:///var/storage/secattach/20260911/27053248.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MESABI+TRUST++++++++++++++For%3A+Jul+31/27053248.html Fri, 11 Sep 2026 16:31:00 -0400 MSB http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html si-local-file:///var/storage/secattach/20260827/26984629.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html Thu, 27 Aug 2026 07:10:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html si-local-file:///var/storage/secattach/20260827/26984629.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html Thu, 27 Aug 2026 07:10:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html si-local-file:///var/storage/secattach/20260827/26984629.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Aug+27/26984629.html Thu, 27 Aug 2026 07:10:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282">http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282</a></p> <p> Filed on: August 27, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html Thu, 27 Aug 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282">http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282</a></p> <p> Filed on: August 27, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html Thu, 27 Aug 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282">http://archive.fast-edgar.com/20260827/A5L2B22CZ222H2Z2222R22ZZJTRQL9Y25282</a></p> <p> Filed on: August 27, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++MESOBLAST+LTD+++++++++++++For%3A+Jun+30/26984227.html Thu, 27 Aug 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Globe+Newswire/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380 http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html <p align="center"><strong><em>RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment</em></strong></p> <p align="center"><strong><em>Financial Results and Operational Update for Full Year Ended June 30, 2026 </em></strong></p> <p align="justify">NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).</p> <p align="justify">Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. http://www.streetinsider.com/Press+Releases/Mesoblast+Reports+Substantial+Revenue+Growth+to+US%24120M/26983281.html Wed, 26 Aug 2026 20:32:00 -0400 A.06822034 A.07309385 A.40866182 A.60012014 MESO MSB O.01273089 O.05851094 O.20026344 O.20043539 O.40440380